Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board  >  Advaxis, Inc.    

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Advaxis, Inc. : UPenn Doses First Two Dogs in ADXS-HER2 Canine Osteosarcoma Study

share with twitter share with LinkedIn share with facebook
share via e-mail
08/02/2012 | 02:10pm CEST

Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first two dogs have been dosed in the University of Pennsylvania School of Veterinary Medicine study of ADXS-HER2 for canine osteosarcoma.

Under the direction of Dr. Nicola Mason, Chair in Companion Animal Medicine at the University of Pennsylvania School of Veterinary Medicine, ADXS-HER2 is being used to treat dogs suffering from bone cancer. Canine osteosarcoma is a leading killer of large breed dogs that causes tumors to form on long leg bones. The traditional treatment is immediate amputation and, even with subsequent chemotherapy, the cancer typically metastasizes to the lungs, causing death in 6-12 months.

In this trial, dogs that have undergone standard of care treatment for osteosarcoma; including limb amputation and follow up chemotherapy, and that over-express the tumor marker HER-2/neu in their tumors, are treated with Advaxis agent ADXS-HER2. This immunotherapy is designed to stimulate the dog's immune system to attack cancer cells that express the HER-2/neu marker. The goal is to elicit anti-tumor immunity and prolong survival.

"We don't have to wait years to see if we are having an effect," commented Dr. Nicola Mason. "If we find that these canine patients survive over 12 months, then that is a strong indication that this immunotherapy is in fact providing a therapeutic benefit."

For more information about the study please visit the Mason Bone Cancer Study webpage.

Links to press that the trial has attracted can be found in the events and presentations section of the Advaxis website.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.

In April 2012, Advaxis' lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional information is available at the World Vaccine Congress website.

Advaxis' lead construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research - UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2011, which is available at www.sec.gov. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

Advaxis, Inc.
Diana Moore, 609-452-9814
Director, Investor Relations & Business Development

© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ADVAXIS, INC.
09/25ADVAXIS : to Present at the Cantor Fitzgerald Global Healthcare Conference
09/11ADVAXIS, INC. : Entry into a Material Definitive Agreement, Other Events, Financ..
09/11ADVAXIS : Announces Closing of Its Public Offering of Common Stock and Warrants
09/10ADVAXIS, INC. : Results of Operations and Financial Condition, Financial Stateme..
09/10ADVAXIS : Management's Discussion and Analysis of Financial Condition and Result..
09/10ADVAXIS : Fiscal 3Q Earnings Snapshot
09/10ADVAXIS : Reports Fiscal 2018 Third Quarter Business Highlights and Financial Re..
09/07ADVAXIS, INC. : Results of Operations and Financial Condition (form 8-K)
09/07ADVAXIS : Announces Pricing of Its Public Offering of Common Stock and Warrants
09/06ADVAXIS, INC. : Announces Proposed Underwritten Public Offering of Common Stock ..
More news
Financials ($)
Sales 2018 6,27 M
EBIT 2018 -60,1 M
Net income 2018 -57,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 8,55x
Capi. / Sales 2019 9,39x
Capitalization 53,6 M
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 3,33 $
Spread / Average Target 391%
EPS Revisions
Kenneth A. Berlin President, Chief Executive Officer & Director
David Sidransky Chairman
Molly Henderson Chief Financial Officer & Executive Vice President
Robert G. Petit Chief Scientific Officer & Executive VP
Al Blunt Vice President-Medical
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%29 133
LONZA GROUP18.00%23 235